share_log

HC Wainwright & Co. Maintains Buy on Genmab, Maintains $50 Price Target

Benzinga ·  Jan 8 22:11  · Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment